The effect of Shugan-Jieyu capsule combined with pramipexole in treatment of parkinson's disease depression
10.3969/j.issn.1005-1678.2017.05.113
- VernacularTitle:舒肝解郁胶囊联合普拉克索对帕金森病抑郁的治疗效果
- Author:
Zhengxiang HU
;
Xiaodong LU
;
Chen CHENG
- Keywords:
parkinson's disease;
depression;
pramipexole;
Shugan-Jieyu capsule
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(5):335-337
- CountryChina
- Language:Chinese
-
Abstract:
Objective Evaluating the effect of Shugan-Jieyu capsule combined with pramipexole on depressive symptoms in parkinson's disease(PD) patients.MethodsAccording to the criteria of including and excluding, we collected 63 PD depression cases who visited doctors at neurological outpatient room between June 2014 and April 2016.35 cases only treated with pramipexole, designed as pramipexole group, and 28 cases treated with pramipexole and Shugan-Jieyu capsule, designed as combined treatment group.The Hamilton depression scale(HAMD), activities of daily living scale(ADL) and unified Parkinson's disease rating scale-part III(UPDRS-III) were assessed at baseling, week 6 and week 9.ResultsAt week 9, HAMD was (17.71±6.78) in pramipexole group versus (14.32±4.81) in combined treatment group, there was significant difference between the two groups(P=0.029), As for HAMDΔ9, analysis did show a significant difference(pramipexole group (-11.06±3.27) vs combined group (-14.93±6.24);P=0.002).Analysis showed a significant difference as for ADLΔ6(pramipexole group (-2.37±1.31) vs combined group (-3.57±2.04);P=0.006) at week 6.There was no significant difference between groups for the reduction in total UPDRS-III scale.No serious adverse event was recorded during treatment of depression.ConclusionShugan-Jieyu capsule combined with pramipexole did have significant effects versus pramipexole on depressive symptoms in PD patients.
